Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AEON Biopharma, Inc. (AEON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/16/2025: AEON (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.2
1 Year Target Price $7.2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.1% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.03M USD | Price to earnings Ratio - | 1Y Target Price 7.2 |
Price to earnings Ratio - | 1Y Target Price 7.2 | ||
Volume (30-day avg) 1 | Beta 0.57 | 52 Weeks Range 0.38 - 215.31 | Updated Date 07/16/2025 |
52 Weeks Range 0.38 - 215.31 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 303.08 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -158.88% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 1.16 | Enterprise Value 13588328 | Price to Sales(TTM) 97.16 |
Enterprise Value 13588328 | Price to Sales(TTM) 97.16 | ||
Enterprise Value to Revenue 201.68 | Enterprise Value to EBITDA -5.89 | Shares Outstanding 11305400 | Shares Floating 7857908 |
Shares Outstanding 11305400 | Shares Floating 7857908 | ||
Percent Insiders 24.46 | Percent Institutions 14.66 |
Upturn AI SWOT
AEON Biopharma, Inc.
Company Overview
History and Background
AEON Biopharma, Inc. is a biopharmaceutical company focused on developing botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for a variety of indications, including chronic migraine, cervical dystonia, and gastroparesis. It was founded with the goal of improving treatment options for these debilitating conditions. Specific founding year and early milestones are not clearly stated in readily available resources. Their focus is on regulatory approval and commercialization.
Core Business Areas
- Therapeutic Development: Development of ABP-450 for neurological and gastrointestinal disorders.
- Clinical Trials: Conducting clinical trials to assess the safety and efficacy of ABP-450.
- Regulatory Affairs: Navigating regulatory approval processes with the FDA.
- Commercialization: Preparing for the commercial launch of ABP-450 upon approval.
Leadership and Structure
AEON Biopharma, Inc. has a leadership team comprised of individuals with experience in the pharmaceutical industry, clinical development, and commercialization. The organizational structure is typical for a biotech company, with departments focused on research and development, clinical operations, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- ABP-450 (prabotulinumtoxinA): ABP-450 is AEON's lead product candidate. It is being developed as a botulinum toxin injection for the treatment of chronic migraine, cervical dystonia, and gastroparesis. Market share is currently 0% as the product is not yet approved. Competitors include Allergan (Botox), Ipsen (Dysport), Merz (Xeomin), and Revance Therapeutics (Daxxify). Potential revenue upon approval across indications could be significant, but no concrete data is available currently. Targetting markets currently serviced by Allergan etc
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. The market for botulinum toxin products is well-established, but AEON is attempting to carve a niche through potentially improved efficacy or safety.
Positioning
AEON is positioned as a company seeking to provide alternative treatment options using a botulinum toxin product. The competitive advantage depends on the clinical trial results and the demonstrated efficacy and safety profile of ABP-450 compared to existing products.
Total Addressable Market (TAM)
The total addressable market for botulinum toxin products is estimated to be in the billions of dollars annually across the various indications AEON is targeting. AEON's position depends on successful clinical trials and regulatory approvals and ability to capture some of this current TAM which is dominated by Allergan and others
Upturn SWOT Analysis
Strengths
- Focused pipeline on botulinum toxin therapeutics
- Potential for improved efficacy/safety profile compared to existing products
- Experienced management team in pharmaceutical development
Weaknesses
- Currently no approved products, leading to zero revenue
- High dependence on the success of ABP-450
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Potential to gain market share in the botulinum toxin market upon approval
- Expansion into new therapeutic indications for ABP-450
- Partnerships or collaborations with larger pharmaceutical companies
Threats
- Failure to obtain regulatory approval for ABP-450
- Competition from established botulinum toxin products
- Adverse events or safety concerns associated with ABP-450
Competitors and Market Share
Key Competitors
- AGN
- IPN
- MRZ
- RVNC
Competitive Landscape
AEON faces a highly competitive landscape dominated by established players with approved botulinum toxin products. AEON's success depends on demonstrating a superior profile for ABP-450.
Growth Trajectory and Initiatives
Historical Growth: No historical revenue growth due to the company being pre-revenue.
Future Projections: Future growth is dependent on the approval and commercial success of ABP-450. Analyst estimates are not readily available. Would need to pull recent analyst reports for projections.
Recent Initiatives: Recent initiatives include ongoing clinical trials for ABP-450 across the target indications and preparation for regulatory submissions.
Summary
AEON Biopharma is a high-risk, high-reward biopharmaceutical company focused on developing a botulinum toxin product. The company's success hinges on positive clinical trial outcomes and regulatory approval. While the company operates in a competitive market dominated by established players, it has the opportunity to capture market share if its product demonstrates superior efficacy and safety. Investors should carefully consider the risks associated with pre-revenue biotech companies and the potential for clinical trial setbacks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share values are estimates. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AEON Biopharma, Inc.
Exchange NYSE MKT | Headquaters Irvine, CA, United States | ||
IPO Launch date 2021-04-12 | President, CEO & Director Mr. Robert Bancroft | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.aeonbiopharma.com |
Full time employees 5 | Website https://www.aeonbiopharma.com | ||
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.